Drugs / Exosome-MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05216562 | Jul 2021 → Jun 2022 | COVID-19 | Dermama Biotechnology Laboratory | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exosome-MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05216562 ↗ |